30 Day Trial

aap Implantate 3Q15 Revenue in Line with Expectations


aap Implantate posted preliminary 3Q15 sales of €8.4MM (~US $9.5MM), +7% from 3Q14, and YTD15 sales of €22.0MM (~$25MM), flat vs. the prior year.

For 3Q15, aap reported trauma sales of ~$3.3MM, -14%, due in part to business developments in BRIC and SMIT regions including delays in product approval that affected 1st shipments to Brazil. Further, the U.S. has not yet offered a significant sales contribution due in part to administrative hold-ups.

Biomaterials 3Q business reached ~$6.1MM, +27%, driven by bone cement sales that improved from 2Q15.

Source: aap Implantate AG